Why The Cipher Pharmaceuticals (TSX:CPH) Story Is Shifting As Analysts Lift Valuation Targets

Web Desk May 23, 2026

0 7 3 minutes read

Why The Cipher Pharmaceuticals (TSX:CPH) Story Is Shifting As Analysts Lift Valuation Targets

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

Cipher Pharmaceuticals is back in focus as analysts refresh their models, with one key shift being a move in published price targets from CA$20 to CA$22 and a separate fair value estimate moving from CA$17.90 to CA$20.64. These higher targets are being framed as a reflection of stronger conviction rather than a call for a major change in the company’s current business plan. Read on to see what is driving the evolving analyst narrative and how you can track it over time.

Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Cipher Pharmaceuticals.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Stifel has been steadily marking Cipher Pharmaceuticals higher, lifting its price target from C$20 to C$21 in March 2026 and then to C$22 in May 2026. This signals growing conviction in the stock’s risk or reward profile.
The repeated reaffirmation of a Buy rating by Stifel suggests the firm sees the current share price as offering upside potential relative to its C$22 target, based on its own valuation work.

🐻 Bearish Takeaways

The only published view in the recent data set comes from a single firm, Stifel, so you are working with a limited set of external opinions rather than a broad cross section of analyst coverage.
Target revisions and ratings are opinion based and do not spell out detailed execution or product risks, so investors still need to weigh factors such as pipeline progress, competition, and regulatory outcomes independently.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!

TSX:CPH 1-Year Stock Price Chart

See how Cipher Pharmaceuticals’ fair value stacks up across multiple valuation models — not just analyst targets.

What’s in the News

Cipher Pharmaceuticals’ board has authorized a new normal course issuer bid, allowing the company to repurchase up to 1,490,343 common shares, or 5.87% of its issued and outstanding capital. The program will be funded from cash and is set to run until May 4, 2027.
Under a prior buyback that began on May 1, 2025, Cipher Pharmaceuticals repurchased 160,962 shares for CA$2.29 million between October 1 and December 31, 2025, bringing total repurchases under that program to 532,940 shares for CA$7.41 million.
CaryHealth has launched a direct to patient platform for Natroba in partnership with Cipher Pharmaceuticals US LLC, offering telehealth services, pharmacy fulfillment and real time prescription tracking.
Interim CEO Craig Mull has said Cipher Pharmaceuticals is actively discussing acquisitions and in licensing opportunities, including company level deals that could add size, scale and cash flow.

How This Changes the Fair Value For Cipher Pharmaceuticals

Fair value in the refreshed model is set at CA$20.64, up from CA$17.90.
Revenue growth assumption is set at 9.45%, compared with 7.73% previously.
Net profit margin assumption is set at 42.15%, compared with 26.96% previously.
Future P/E multiple is set at 16.64x, compared with 31.86x previously.
Discount rate is set at 6.35%, compared with 5.97% previously.

Never Miss an Update: Follow The Narrative

Narratives link a company’s business story to the assumptions behind its forecasts and fair value, so you can see why the numbers look the way they do. They refresh as new data, deals, and guidance come through.

Head over to the Simply Wall St Community and follow the Narrative on Cipher Pharmaceuticals to stay up to date on:

How Natroba expansion, telemedicine and direct to patient channels are being used to build out new dermatology revenue streams across the U.S., Canada and global markets.
How capital allocation choices such as share buybacks, debt reduction and potential in licensing or acquisitions tie into earnings and margin expectations.
Key risks around reliance on Natroba, erosion of legacy Absorica royalties, rising SG&A costs and uncertain M&A or out licensing outcomes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CPH.TO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com